ArticleImmunology letters2008
Search for potential target site of nucleocapsid gene for the design of an epitope-based SARS DNA vaccine.
Article in Immunology letters, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Designing a multi-epitope universal vaccine for concurrent infections of SARS-CoV-2 and influenza viruses using an immunoinformatics approach.BMC infectious diseases · 2025Article
- Feature selection for effective prediction of SARS-COV-2 using machine learning.Genes & genomics · 2024Article
- Next-Generation Vaccines Against COVID-19 Variants: Beyond the Spike Protein.Zoonoses (Shannon, Ireland) · 2023Article
- Dimerization of SARS-CoV-2 nucleocapsid protein affects sensitivity of ELISA based diagnostics of COVID-19.International journal of biological macromolecules · 2022Article
- Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein.Molecular immunology · 2022Article
- Article
- Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies.Translational research : the journal of laboratory and clinical medicine · 2021Article
- In-silico study of peptide-protein interaction of antimicrobial peptides potentially targeting SARS and SARS-CoV-2 nucleocapsid protein.In silico pharmacology · 2021Article
- Designing of Nucleocapsid Protein Based Novel Multi-epitope Vaccine Against SARS-COV-2 Using Immunoinformatics Approach.International journal of peptide research and therapeutics · 2021Article
- COVID-19 vaccine: where are we now and where should we go?Expert review of vaccines · 2021Review
- Platforms Exploited for SARS-CoV-2 Vaccine Development.Vaccines · 2020Review
- Development of SARS-CoV-2 Nucleocapsid Specific Monoclonal Antibodies.bioRxiv : the preprint server for biology · 2020Article
- The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development.Journal of virology · 2020Article
- Analysis of preferred codon usage in the coronavirus N genes and their implications for genome evolution and vaccine design.Journal of virological methods · 2020Article
- Reverse genetic systems: Rational design of coronavirus live attenuated vaccines with immune sequelae.Advances in virus research · 2020Review
- Article
- A review of vaccine development and research for industry animals in Korea.Clinical and experimental vaccine research · 2012Article
- Identification of a novel conserved HLA-A*0201-restricted epitope from the spike protein of SARS-CoV.BMC immunology · 2009Article
- The spike protein of SARS-CoV--a target for vaccine and therapeutic development.Nature reviews. Microbiology · 2009Review
- Vaccine development against coronavirus (2003 to present): An overview, recent advances, current scenario, opportunities and challenges.Diabetes & metabolic syndromeReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is believed today that nucleocapsid protein (N) of severe acute respiratory syndrome (SARS)-CoV is one of the most promising antigen candidates for vaccine design. In this study, three fragments [N1 (residues: 1-422); N2 (residues: 1-109); N3 (residues: 110-422)] of N protein of SARS-CoV were expressed in Escherichia coli and analyzed by pooled sera of convalescence phase of SARS patients. Three gene fragments [N1 (1-1269 nt), N2 (1-327 nt) and N3 (328-1269 nt)-expressing the same proteins of N1, N2 and N3, respectively] of SARS-N were cloned into pVAX-1 and used to immunize BALB/c mice by electroporation. Humoral (by enzyme-linked immunosorbent assay, ELISA) and cellular (by cell proliferation and CD4(+):CD8(+) assay) immunity was detected by using recombinant N1 and N3 specific antigen. Results showed that N1 and N3 fragments of N protein expressed by E. coli were able to react with sera of SARS patients but N2 could not. Specific humoral and cellular immunity in mice could be induced significantly by inoculating SARS-CoV N1 and N3 DNA vaccine. In addition, the immune response levels in N3 were significantly higher for antibody responses (IgG and IgG1 but not IgG2a) and cell proliferation but not in CD4(+):CD8(+) assay compared to N1 vaccine. The identification of antigenic N protein fragments has implications to provide basic information for the design of DNA vaccine against SARS-CoV. The present results not only suggest that DNA immunization with pVax-N3 could be used as potential DNA vaccination approaches to induce antibody in BALB/c mice, but also illustrates that gene immunization with these SARS DNA vaccines can generate different immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.